Stuttgart
15.07.26 | 09:15
0,162 Euro
+3,98 % +0,006
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,161 | 0,162 | 09:35 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.07. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 228 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.06. | Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026 | 397 | Business Wire | All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio,... ► Artikel lesen | |
| 03.06. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 349 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 03.06. | Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying "Triple Healing", a Cellvizio- Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis | 292 | Business Wire | 100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not A decade of converging, multi-center... ► Artikel lesen | |
| 20.05. | Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance Commercial Installation | 383 | Business Wire | IBS-related symptom prevalence in the region is among the highest in the world, reaching an average of 27% An ideal region uniquely positioned for CellTolerance's direct out-of-pocket commercial... ► Artikel lesen | |
| 18.05. | Mauna Kea Technologies Announces Nomination of 3 New Directors | 554 | Business Wire | Their recognized expertise will help accelerate the strategic transformation launched in 2025 Subject to approval at upcoming Annual General Meeting
Regulatory News:
Mauna Kea Technologies... ► Artikel lesen | |
| 04.05. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 325 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 30.04. | Mauna Kea Technologies: Publication of the 2025 Annual Financial Report | 644 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 28.04. | Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio To Be Presented at Digestive Disease Week 2026 | 714 | Business Wire | 10 Cellvizio-related abstracts, including landmark multicenter pancreatic cyst data, AI-driven IBD assessment, and new food intolerance applications, reinforce the breadth and depth of real-time... ► Artikel lesen | |
| 22.04. | Mauna Kea Technologies meldet starkes Wachstum im ersten Quartal 2026 | 1 | Investing.com Deutsch | ||
| 22.04. | Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025 | 785 | Business Wire | Fundamental balance sheet reset achieved through a 70% reduction in financial debt and €20M increase in equity Product sales momentum in 2025 driven by record U.S. sales performance (+38% CER)... ► Artikel lesen | |
| 15.04. | Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth | 412 | Business Wire | Q1 2026 sales reached €1,527K (excluding licensing), an increase of +68% at Constant Exchange Rate CER) and +57% as reported U.S. sales grew +34% CER (+21% reported) and +51% on an invoiced basis... ► Artikel lesen | |
| 08.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 326 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 17.03. | Mauna Kea Technologies Updates Its Financial Calendar | 1.095 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today... ► Artikel lesen | |
| 23.02. | Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom | 802 | Business Wire | These clearances enable the commercialization of Cellvizio in two major markets and accelerate the Group's international expansion First order for the next-generation Cellvizio (Gen 3) platform... ► Artikel lesen | |
| 10.02. | Mauna Kea Technologies Announces CE MDR Certification For Cellvizio and Its Associated Probes | 519 | Business Wire | A major regulatory milestone in the European commercial expansion strategy Mauna Kea Technologies is the only endomicroscopy company to obtain this certification under the new European regulation
Regulatory... ► Artikel lesen | |
| 06.02. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 525 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.02. | Mauna Kea Technologies Announces New Commercial Organization to Accelerate Growth Outside the United States | 693 | Business Wire | Building on Strong 2025 Momentum with Accelerated Sales Growth in Pancreatic Cysts €1M Milestone for CellTolerance Appointment of Benoit Chardon as Fractional Chief Commercial Officer to Lead... ► Artikel lesen | |
| 26.01. | Mauna Kea Technologies Announces Initiation of Coverage by Allinvest Securities | 373 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) announces today... ► Artikel lesen | |
| 21.01. | Mauna Kea Technologies Announces Its 2026 Financial Calendar Highlighted by Its Participation in Several Investor Forums | 902 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today... ► Artikel lesen |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,072 | +2,86 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| FAMICORD | 3,240 | +3,85 % | FamiCord plant Wechsel in das Scale-Segment der Frankfurter Börse | Der Vorstand der FamiCord AG, die früher als Vita 34 firmierte, will die Börsennotierung des Unternehmens vom regulierten Markt (Prime Standard) in das Freiverkehrssegment Scale der Frankfurter Wertpapierbörse... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,610 | -4,04 % | Geratherm Medical AG: Ein herausforderndes GJ26 folgt auf ein schwieriges GJ25; Kursziel gesenkt, KAUFEN. | Geratherm hat die Ergebnisse für das Geschäftsjahr 2025 veröffentlicht. Die Umsätze stiegen um 6 %, jedoch führten erhebliche makroökonomische Gegenwinde, Wettbewerb aus China und inländischer Kostendruck... ► Artikel lesen | |
| PLUS THERAPEUTICS | 3,650 | +2,38 % | Plus Therapeutics Inc.: Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide in Leptomeningeal Metastases Monitoring | HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network (NCCN)... ► Artikel lesen | |
| MEDICLIN | 4,100 | 0,00 % | EQS-RPT: MEDICLIN AG: Veröffentlichung gemäß § 111c AktG mit dem Ziel der europaweiten Verbreitung | EQS Mitteilung über Geschäfte mit nahestehenden Personen: MEDICLIN AG
/ Veröffentlichung gemäß § 111c AktG
MEDICLIN AG: Veröffentlichung gemäß § 111c AktG mit dem Ziel der europaweiten... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,040 | +3,55 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds | $4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants
SEATTLE, June 12, 2026 /PRNewswire/... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| VERU | 2,300 | -0,43 % | Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA... | REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesen | |
| LIFEWARD | 8,050 | +0,62 % | Lifeward Ltd.: Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing | HUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio... ► Artikel lesen | |
| LIGHT AI | 0,144 | -4,95 % | Light AI Inc: Light AI earns ISO, MDSAP medical device certifications | ||
| BRIGHTSPRING HEALTH SERVICES | 69,68 | +0,01 % | Raymond James initiates BrightSpring Health stock with outperform rating | ||
| BILLIONTOONE | 124,59 | -0,22 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,210 | +0,05 % | Kaplan Fox & Kilsheimer LLP: Kaplan Fox Alerts Investors of Alignment Healthcare, Inc. (ALHC) to an Investigation of Potential Securities Law Violations | New York, New York--(Newsfile Corp. - July 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or... ► Artikel lesen | |
| BETA BIONICS | 16,860 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,162 Euro und damit +3,98 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.